Industry Reports
Commercializing Biopharmaceutical Innovation In A New Era
The new era in biopharmaceutical development promises to usher in a slew of breakthrough medicines, including cures for treatment options. More than 7,800 medications are in clinical development, spanning a wide variety of therapeutic categories from cancer to cardiovascular...
Industry Reports
Pfizer Shells Out $11.6 Bn. For Biohaven- Largest Since 2016
Pfizer will pay $11.6 billion for migraine medicine manufacturer Biohaven Pharmaceutical, signifying the company's largest acquisition since 2016, as it seeks to expand its inventory ahead of patent expiration dates for many cancer drugs.
Pfizer will gain access to Biohaven's...
Industry Reports
Japan Drug Lobby Asserts Pricing Scheme Driving Drug Crisis
For the first time in the week starting May 16th, Japan's three major pharmaceutical trade associations joined forces to call for changes to the government's drug pricing structure in order to prevent missing out on new drug innovation and...
Industry Reports
Amid Global Setbacks, Indian Pharma Exports Grow In 2021-22
The Government of India recently announced that the pharmaceutical sector had its best-ever export performance in 2021-22, with a phenomenal increase of about $10 billion in just eight years. Since 2013-14, the country's pharmaceutical sector has grown by 103%, from...
Industry Reports
Samsung Biologics Reports First Quarter 2022 Financial Results
Samsung Biologics, the world’s leading contract development and manufacturing organization, announced strong financial results for the first quarter of fiscal year 2022.
John Rim, CEO of Samsung Biologics, stated, “Samsung Biologics’ strong start to the 2022 fiscal year was driven...
Industry Reports
Tong Ren Tang Technologies Co. Ltd. Strong Performance Revenue 5.4billion and Net Profit 867million in 2021
With the strong support and promotion of the government, the traditional Chinese medicine industry has inherited from the tradition and developed innovatively and rapidly. 2021 is the revolutionary year of Tong Ren Tang Technologies (01666). The company achieved excellent...
Industry Reports
Samsung Biologics Reports Fourth Quarter & Fiscal Year 2021 Financial Results
Samsung Biologics, the world’s leading contract development and manufacturing organization, announced strong financial results for the fourth quarter and record-high earnings for the fiscal year of 2021.
John Rim, CEO of Samsung Biologics, stated, “With a steep increase in demand...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
